Diagnostic testing solutions company releases COVID-19 dashboard showing rising infection rates among younger Americans
NEW YORK--(BUSINESS WIRE)--PWNHealth (PWN), a national clinician network and leading provider of diagnostic testing solutions and telehealth services, today announced that its national testing platform has supported more than 5 million COVID-19 polymerase chain reaction (PCR) and antibody tests combined since April 2020. Since the onset of the COVID-19 pandemic, PWNHealth and its partners have launched and maintained 45 different programs that conduct as many as 80,000 daily tests in all 50 states, Washington, D.C. and Puerto Rico. The company’s national footprint and support for millions of tests provides a snapshot of key pandemic trends.
PWNHealth provides a comprehensive framework for implementing large-scale programs such as drive-thru test sites, at-home testing and employer screening programs. PWN’s solutions also deliver clinical oversight, lab connectivity and patient follow-up via telehealth for these programs. In addition, the company manages results reporting to state and county Departments of Health.
“Our team has been working incredibly hard to do our part and support the critical need for national testing,” said Sanjay Pingle, CEO of PWNHealth. “We are proud to reach this milestone, as it serves as a testament to our tremendous impact on millions of Americans. If you’ve been to a drive-thru test site or received an at-home test, it’s likely that PWN has been providing services to you behind the scenes.”
Reflective of PWN’s five million test milestone, the company today additionally released its COVID-19 PCR and antibody testing dashboard to the public. The continuously-updated online hub offers valuable COVID-19 testing data, including national and state-by-state breakdowns of test volumes with positive returns. PWN’s dashboard additionally offers insights into monthly test orders and positivity rates by age and gender logged since April 2020, indicating a concerning rise of positive results among younger Americans.
“As soon as the first PCR test was available in the U.S., PWN deployed our infrastructure to support COVID-19 testing,” said Bill Paquin, Chief Commercial Officer of PWNHealth. “Our clinical, technical and regulatory infrastructure allows public and private partners to scale testing safely. It has been humbling to do what we can to make a difference. Passing the 5 million test milestone is a strong reminder of the scope of the challenge before us, and inspires us to continue expanding our services so that millions more of our neighbors will have access to high quality testing.”
"As the pandemic evolves, PWN will continue to update and leverage our data to make more efficient and accessible testing resources available to the public," added Doug Elwood, MD, Chief Medical Officer of PWNHealth. "The sheer volume of testing managed by our platform provides valuable insights that can further preserve and improve public health as we look ahead to 2021 and beyond.”
PWNHealth is a national clinician network working to improve early detection and prevention of disease using advanced diagnostics and telehealth. PWN services all 50 states and Puerto Rico with telehealth and telegenetic services. Our model enables safe and easy access to diagnostic testing, ensuring clinical validity, utility, quality consumer education, access to clinicians, and the ability to implement national programs seamlessly. Our solutions provide the clinical, legal, and technological framework to facilitate population-scale testing across key healthcare markets. Through integration with more than 80 CLIA-certified labs and support of over 3,000 test types, we are shaping a new paradigm in healthcare. We believe that empowering people with convenient access to clinically actionable testing has the power to change lives, improve outcomes, and create a healthier world. PWNHealth is backed by leading growth equity firms Spectrum Equity and the Blue Venture Fund (BVF). For more information, visit www.pwnhealth.com. Follow us on Twitter, LinkedIn and Medium.
Marli Grossman (email@example.com)